A Phase 2 interventional study of SAR442501 in Osteochondrodysplasia, sponsored by Sanofi. Terminated at 9 sites in 5 countries. Open to participants aged 0 Days to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
Up to approximately 275 weeks: 3 weeks Screening + 52 weeks primary treatment period + up to approximately 216 weeks extended treatment period+ 4 weeks follow-up.
41 studies on the registry are indexed under Osteochondrodysplasias; 11 are open to participants now.
This study's enrollment of 16 is below the median of 77 across 19 interventional studies indexed under Osteochondrodysplasias.
Browse Osteochondrodysplasias studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Drug: SAR442501
Drug: SAR442501
Drug: SAR442501
Solution for injection; Subcutaneous injection
Stage 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any untoward medical occurrence (whether considered to be related to study drug or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect; or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study drug up to 5 days post last dose of the study drug.
Time frame: From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
Stage 1: Change From Baseline to Weeks 26 and 52 in Growth Velocity Z-Score
Post-treatment annualized growth velocity (AGV) was calculated from height measurements collected during the study. AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25, where interval length in days was calculated as (Date 2 - Date 1+1). Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= \[(AGV/M)\^L-1\]/(LxS); If L= 0: Z= ln(AGV/M)/S. A Z score of 0 represents the mean AGV of the reference achondroplasia (ACH) population. For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations. Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms. Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Annualized Growth Velocity
The AGV was defined as follows: (Height at Date 2 - height at Date 1) divided by interval length in days x 365.25, where the interval length in days was calculated as (Date 2 - Date 1 +1) days. The post-treatment AGV was calculated from height measurements collected during the study. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Height Z-Score
Post-treatment AGV was calculated from height measurements collected during the study. AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25, where interval length in days was calculated as (Date 2 - Date 1+1). Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= \[(AGV/M)\^L-1\]/(LxS); If L= 0: Z= ln(AGV/M)/S. A Z score of 0 represents the mean AGV of the reference population (ACH). For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations. Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms. Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper to Lower Body Segment Ratio
The upper to lower body segment ratio was calculated by (standing height or total length - lower body segment length) divided by lower body segment length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper to Lower Extremity Ratio
The upper to lower extremity ratio was calculated by (upper arm + forearm length) divided by (upper leg + lower leg length). The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Sitting to Standing Height Ratio
The sitting to standing height ratio was calculated by sitting height divided by standing height, or crown to rump length divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Arm Span to Height Ratio
The arm span to height ratio was calculated by arm span divided by standing height, or arm span divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper Arm to Forearm Length Ratio
The upper arm to forearm length ratio was calculated by upper arm length divided by forearm length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Upper Leg to Lower Leg Ratio
The upper leg to lower leg length ratio was calculated by upper leg length divided by lower leg length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Head Circumference to Height Ratio
The head circumference to height ratio was calculated by head circumference divided by standing height, or head circumference divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 2: Change From Baseline to Week 52 in Brainstem, Skull, and Spine Morphometric and Volumetric Parameters
The magnetic resonance imaging was planned to be collected to measure foramen magnum and other brainstem, skull, and spine morphometric parameters in Stage 2 participants. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Week 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Social Score, Emotional Score, and School Functioning Score
The pediatric quality of life (PedsQL) Generic Core Scales assesses pediatric health related quality of life (HRQOL) across functioning domains. Items use a 5-point scale (0=Never to 4=Almost Always). Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), where higher scores indicate better quality of life (fewer problems). Domain scores for Social, Emotional, and School Functioning are calculated from the transformed item scores. If more than 50% of items in a domain are missing, the domain score is not computed. If at least 50% are completed, the domain score equals the mean of the non missing transformed item scores. All domain scores range from 0 (almost always) to 100 (never), with higher scores indicate better HRQOL. Baseline was defined as the last available value prior to the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Psychosocial Health Summary Score, Physical Health Summary Score, and Total Score
The PedsQL core scale was a brief, standardized, generic instrument that was used to measure HRQOL in various pediatric conditions. Psychosocial health summary scores were the meaning of item scores in emotional, social, and school functioning scales; and Physical health summary scores were the meaning of item scores in physical scale. Total score was the mean of all the item scores in all scales. Psychosocial and physical health summary scores and total scores each ranged from 0 (almost always) to 100 (never). Higher scores indicate better HRQOL. For participants aged 5 to 7, only parents completed the questionnaire. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Mobility Score
The screening tool for everyday mobility and symptoms (STEMS) was completed by clinicians for participants 5 years of age and older. The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community. Mobility aides were recorded using numeric 5-point rating scale, score ranged from 1 to 5, where 1= independent on all surfaces including stairs, 2= use of sticks, 3= use of crutches, 4= use of wheeled walking device, and 5= use of wheelchair or mobility scooter. Lower score indicated the better outcome. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Participants Reported Symptoms
The STEMS was completed by clinicians for participants 5 years of age and older. The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community. Participant reported symptoms were recorded using letters where A= no pain or fatigue, B1= pain only, B2= fatigue and C= pain and fatigue. This was completed for each of the 3 environments resulting in 3 scores, whereby the numeric rating reflects the use of mobility aides and the letter reflects the symptoms. The baseline value was defined as the last available value before the first dose of study drug. Only participants with a Baseline response of "A" were included in the "A to A," "A to B1," and "A to missing" categories at each time point. Similarly, only participants with a Baseline response of "B1" were included in the "B1 to A" and "B1 to missing" categories at each time point.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue Scores and Total Score
The PedsQL Multidimensional Fatigue Scale measures fatigue across 3 subscales:General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue. Items are rated on a 5 point scale (0=Never to 4=Almost Always). Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), with higher scores indicate less fatigue and better functioning. Subscale scores are calculated as mean of transformed item scores within each subscale. A Total Score was calculated as mean of all transformed items across subscales. If more than 50% of items are missing within a subscale or across total scale, corresponding score is not computed. If at least 50% are completed, scores are calculated as mean of non missing transformed items. All scores range from 0 (no pain) to 100 (severe pain), with higher scores indicate less fatigue. Baseline was defined as last available value prior to first dose of study drug. For participants aged 5-7 years, only parent proxy report was completed.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Current Pain and Worst Pain Rating (PPQ) Score
The PedsQL PPQ assesses current pain and worst pain intensity in the last week using a visual analog scale as well as pain location using a body map. Current and worst pain were scored separately, and scoring was based on the line length to the nearest 0.5 centimeter (5 millimeter). The score ranged from 0 (no pain) to 100 (severe pain), where higher scores indicated greater levels of pain intensity. The PedsQL PPQ was only administered in participants ages 5 years of age and older using both self-report (ages 8 and older) and parent proxy report (ages 5 and older) forms in all countries. For participants aged 5 to 7, only parents completed the questionnaire. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 2: Change From Baseline to Week 52 in Achievement of Gross Motor, Fine Motor, Communication, and Feeding Milestones
For Stage 2 participants, achievement of developmental milestones was planned to be assessed using the ACH developmental recording form. This form allows developmental milestones to be recorded and was not a formalized screening tool or assessment. The form measures the domains of gross motor function, fine motor function, communication and feeding via participant reports to the Investigator. The form depicts the cumulative percentage distributions for children with ACH for each item as well as norms for reference based on the Denver II test, where available. Data collected via this form was planned to be evaluated descriptively to explore the age at which participants in this study achieve developmental milestones. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Week 52
Stage 1: Plasma Concentration of SAR442501
Blood samples are collected to determine plasma concentration of SAR442501.
Time frame: Pre-dose and 6, 24 and 72 hours post dose on Day 1; Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
Stage 1: Maximum Observed Plasma Concentration (Cmax) of SAR442501
Blood samples are collected to determine Cmax of SAR442501. The Cmax of SAR442501 was calculated using non-compartmental method.
Time frame: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
Stage 1: Time to Reach the Maximum Concentration (Tmax) of SAR442501
Blood samples are collected to determine tmax of SAR442501. The tmax of SAR442501 was calculated using non-compartmental method.
Time frame: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
Stage 1: Area Under the Concentration Versus Time Curve From Time 0 to 72 Hours After Study Drug Administration (AUC0-tau) of SAR442501
Blood samples are collected to determine AUC0-tau of SAR442501. The AUC0-tau of SAR442501 was calculated using non-compartmental method.
Time frame: Pre-dose and 3, 6, 12, 24 and 72 hours post dose on Day 57
Stage 1: Minimum Plasma Concentration (Ctrough) of SAR442501
Blood samples are collected to determine Ctrough of SAR442501. The Ctrough of SAR442501 was calculated using non-compartmental method.
Time frame: Pre-dose on Days 8, 29, 57, 92, 183, 274, 365 and 449
Stage 1: Change From Baseline to Week 26 in Collagen X Biomarker (CXM) Level
Serum samples were collected to assess the change in CXM level with study drug. The CXM was also named PRO-C10 because the biomarker assay used was aimed to target the recognition of the C terminus of the NC1 domain of type X collagen. The baseline value was defined as the last available value before the first dose of study drug. Change from baseline in CXM level has been reported.
Time frame: Baseline (Day 1) and Week 26
Stage 1: Change From Baseline to Weeks 26 and 52 in Osteocalcin Level
Serum samples were collected to assess the change in osteocalcin level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Bone-Specific Alkaline Phosphatase Level
Serum samples were collected to assess the change in bone-specific alkaline phosphatase level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Procollagen Type 1 N-Terminal Propeptide (P1NP) Level
Serum samples were collected to assess the change in P1NP level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Change From Baseline to Weeks 26 and 52 in Collagen-Type 1 C-Telopeptide (CTX) Level
Serum samples were collected to assess the change in CTX level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
Stage 1: Number of Participants With Anti-drug Antibodies (ADA) to SAR442501
Serum samples were collected to assess the antibodies to SAR442501. Samples were screened and then confirmed for antibodies binding to SAR442501 and the titer of confirmed positive samples were reported. Positive ADA refers to pre-existing ADA at the pre-dose assessment on Day 1.
Time frame: From the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B)
Stage 2: Number of Participants With Change From Baseline to Weeks 26 and 52 in Neurological Examination Findings
A complete neurological examination included assessment of mental status, motor function and balance, sensory exam, newborn and infant reflexes, muscle stretch reflexes in the older children and evaluation of the cranial nerves. The baseline value was defined as the last available value before the first dose of study drug.
Time frame: Baseline (Day 1) and Weeks 26 and 52
The study was conducted at 6 centers in 4 countries from 10 October 2023 to 12 February 2025. A total of 16 participants who had completed data collection in the study OBS16647 and met the eligibility were enrolled in the study.
| Milestone | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Started | 10 | 6 |
| Completed | 0 | 0 |
| Not completed | 10 | 6 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Study terminated by sponsor decision, which was not related to safety concerns | 8 | 6 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any untoward medical occurrence (whether considered to be related to study drug or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect; or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study drug up to 5 days post last dose of the study drug.
| Participants | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Any TEAE | 5 | 4 |
| Any serious TEAE | 1 | 0 |
| Any AESI | 0 | 0 |
Post-treatment annualized growth velocity (AGV) was calculated from height measurements collected during the study. AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25, where interval length in days was calculated as (Date 2 - Date 1+1). Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= \[(AGV/M)\^L-1\]/(LxS); If L= 0: Z= ln(AGV/M)/S. A Z score of 0 represents the mean AGV of the reference achondroplasia (ACH) population. For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations. Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms. Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
| Z-score | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 2.89 ± 3.75 | 4.58 ± 4.96 |
| Week 52 | 1.45 ± 2.56 | 1.92 ± 2.83 |
The AGV was defined as follows: (Height at Date 2 - height at Date 1) divided by interval length in days x 365.25, where the interval length in days was calculated as (Date 2 - Date 1 +1) days. The post-treatment AGV was calculated from height measurements collected during the study. The baseline value was defined as the last available value before the first dose of study drug.
| centimeter per year | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 1.34 ± 1.83 | 2.63 ± 2.36 |
| Week 52 | 0.53 ± 1.21 | 1.29 ± 1.49 |
Post-treatment AGV was calculated from height measurements collected during the study. AGV was calculated as: AGV (centimeter per year)= (Height at Date 2 - Height at Date 1) divided by interval length in days x 365.25, where interval length in days was calculated as (Date 2 - Date 1+1). Z scores were calculated using LMS methods (Box Cox power L, Median M and Variation S), where appropriate: If L≠ 0: Z= \[(AGV/M)\^L-1\]/(LxS); If L= 0: Z= ln(AGV/M)/S. A Z score of 0 represents the mean AGV of the reference population (ACH). For AGV Z scores in children with ACH: Higher Z scores represent better outcomes, meaning faster linear growth relative to age and sex matched reference populations. Lower Z scores represent worse outcomes, indicating slower growth compared to reference norms. Baseline value was defined as last available pre dose height measurement meeting statistical analysis plan specified time interval definitions.
| Z-score | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 0.07 ± 0.06 | 0.13 ± 0.15 |
| Week 52 | 0.01 ± 0.13 | 0.02 ± 0.30 |
The upper to lower body segment ratio was calculated by (standing height or total length - lower body segment length) divided by lower body segment length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.037 ± 0.060 | -0.047 ± 0.038 |
| Week 52 | -0.060 ± NA | — |
The upper to lower extremity ratio was calculated by (upper arm + forearm length) divided by (upper leg + lower leg length). The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.024 ± 0.025 | -0.023 ± 0.019 |
| Week 52 | -0.030 ± NA | — |
The sitting to standing height ratio was calculated by sitting height divided by standing height, or crown to rump length divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.006 ± 0.013 | 0.003 ± 0.010 |
| Week 52 | 0.000 ± NA | — |
The arm span to height ratio was calculated by arm span divided by standing height, or arm span divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.009 ± 0.013 | -0.005 ± 0.014 |
| Week 52 | 0.020 ± NA | — |
The upper arm to forearm length ratio was calculated by upper arm length divided by forearm length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 0.016 ± 0.062 | -0.002 ± 0.071 |
| Week 52 | 0.070 ± NA | — |
The upper leg to lower leg length ratio was calculated by upper leg length divided by lower leg length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.011 ± 0.032 | -0.003 ± 0.053 |
| Week 52 | -0.030 ± NA | — |
The head circumference to height ratio was calculated by head circumference divided by standing height, or head circumference divided by total length. The baseline value was defined as the last available value before the first dose of study drug.
| ratio | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -0.016 ± 0.005 | -0.013 ± 0.010 |
| Week 52 | -0.030 ± NA | — |
The magnetic resonance imaging was planned to be collected to measure foramen magnum and other brainstem, skull, and spine morphometric parameters in Stage 2 participants. The baseline value was defined as the last available value before the first dose of study drug.
No measurements were reported for this outcome.
The pediatric quality of life (PedsQL) Generic Core Scales assesses pediatric health related quality of life (HRQOL) across functioning domains. Items use a 5-point scale (0=Never to 4=Almost Always). Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), where higher scores indicate better quality of life (fewer problems). Domain scores for Social, Emotional, and School Functioning are calculated from the transformed item scores. If more than 50% of items in a domain are missing, the domain score is not computed. If at least 50% are completed, the domain score equals the mean of the non missing transformed item scores. All domain scores range from 0 (almost always) to 100 (never), with higher scores indicate better HRQOL. Baseline was defined as the last available value prior to the first dose of study drug.
| score on a scale | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Social functioning score: Week 26: 8 to 12 years of age (child report) | -10.00 ± 7.07 | -2.50 ± 21.02 |
| Social functioning score: Week 26: 8 to 12 years of age (parent report) | 7.50 ± 10.61 | 5.00 ± 18.71 |
| Social functioning score: Week 26: 5 to 7 years of age (parent report) | 0.00 ± 6.12 | 2.50 ± 3.54 |
| Social functioning score: Week 52: 5 to 7 years of age (parent report) | 20.00 ± NA | — |
| Emotional functioning score: Week 26: 8 to 12 years of age (child report) | -10.00 ± 28.28 | 11.25 ± 16.52 |
| Emotional functioning score: Week 26: 8 to 12 years of age (parent report) | -2.50 ± 31.82 | 1.25 ± 6.29 |
| Emotional functioning score: Week 26: 5 to 7 years of age (parent report) | 9.00 ± 6.52 | 0.00 ± 0.00 |
| Emotional functioning score: Week 52: 5 to 7 years of age (parent report) | 5.00 ± NA | — |
| School functioning score: Week 26: 8 to 12 years of age (child report) | 20.00 ± 7.07 | -8.75 ± 12.50 |
| School functioning score: Week 26: 8 to 12 years of age (parent report) | 7.50 ± 17.68 | 20.00 ± 23.80 |
| School functioning score: Week 26: 5 to 7 years of age (parent report) | 5.00 ± 10.00 | 5.00 ± 0.00 |
| School functioning score: Week 52: 5 to 7 years of age (parent report) | 10.00 ± NA | — |
The PedsQL core scale was a brief, standardized, generic instrument that was used to measure HRQOL in various pediatric conditions. Psychosocial health summary scores were the meaning of item scores in emotional, social, and school functioning scales; and Physical health summary scores were the meaning of item scores in physical scale. Total score was the mean of all the item scores in all scales. Psychosocial and physical health summary scores and total scores each ranged from 0 (almost always) to 100 (never). Higher scores indicate better HRQOL. For participants aged 5 to 7, only parents completed the questionnaire. The baseline value was defined as the last available value before the first dose of study drug.
| score on a scale | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Psychosocial health summary score: Week 26: 8 to 12 years of age (child report) | 0.00 ± 9.43 | 0.00 ± 14.60 |
| Psychosocial health summary score: Week 26: 8 to 12 years of age (parent report) | 4.17 ± 20.03 | 8.75 ± 15.89 |
| Psychosocial health summary score: Week 26: 5 to 7 years of age (parent report) | 4.67 ± 4.15 | 2.50 ± 1.17 |
| Psychosocial health summary score: Week 52: 5 to 7 years of age (parent report) | 11.66 ± NA | — |
| Physical health summary score: Week 26: 8 to 12 years of age (child report) | -17.19 ± 41.99 | 9.37 ± 12.76 |
| Physical health summary score: Week 26: 8 to 12 years of age (parent report) | 26.56 ± 6.63 | 0.78 ± 19.99 |
| Physical health summary score: Week 26: 5 to 7 years of age (parent report) | -1.87 ± 10.27 | -1.56 ± 11.05 |
| Physical health summary score: Week 52: 5 to 7 years of age (parent report) | 25.00 ± NA | — |
| Total score: Week 26: 8 to 12 years of age (child report) | -5.98 ± 20.75 | 3.26 ± 13.95 |
| Total score: Week 26: 8 to 12 years of age (parent report) | 11.96 ± 10.76 | 5.98 ± 16.09 |
| Total score: Week 26: 5 to 7 years of age (parent report) | 2.39 ± 3.30 | 1.09 ± 3.08 |
| Total score: Week 52: 5 to 7 years of age (parent report) | 16.30 ± NA | — |
The screening tool for everyday mobility and symptoms (STEMS) was completed by clinicians for participants 5 years of age and older. The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community. Mobility aides were recorded using numeric 5-point rating scale, score ranged from 1 to 5, where 1= independent on all surfaces including stairs, 2= use of sticks, 3= use of crutches, 4= use of wheeled walking device, and 5= use of wheelchair or mobility scooter. Lower score indicated the better outcome. The baseline value was defined as the last available value before the first dose of study drug.
| score on a scale | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Mobility - community: Week 26 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Mobility - community: Week 52 | 0.00 ± NA | — |
| Mobility - home: Week 26 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Mobility - home: Week 52 | 0.00 ± NA | — |
| Mobility - school: Week 26 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Mobility - school: Week 52 | 0.00 ± NA | — |
The STEMS was completed by clinicians for participants 5 years of age and older. The STEMS captures mobility, use of mobility aides, and impact of pain and/or fatigue at the end of the day across 3 environments: home, school/work and community. Participant reported symptoms were recorded using letters where A= no pain or fatigue, B1= pain only, B2= fatigue and C= pain and fatigue. This was completed for each of the 3 environments resulting in 3 scores, whereby the numeric rating reflects the use of mobility aides and the letter reflects the symptoms. The baseline value was defined as the last available value before the first dose of study drug. Only participants with a Baseline response of "A" were included in the "A to A," "A to B1," and "A to missing" categories at each time point. Similarly, only participants with a Baseline response of "B1" were included in the "B1 to A" and "B1 to missing" categories at each time point.
| participants | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Self reported symptoms - community: Week 26 - A to A | 5 | 6 |
| Self reported symptoms - community: Week 26 - A to B1 | 1 | 0 |
| Self reported symptoms - community: Week 26 - A to missing | 1 | 0 |
| Self reported symptoms - community: Week 26 - B1 to A | 1 | — |
| Self reported symptoms - community: Week 52 - A to B1 | 1 | 0 |
| Self reported symptoms - community: Week 52 - A to missing | 6 | 6 |
| Self reported symptoms - community: Week 52 - B1 to missing | 1 | — |
| Self reported symptoms - home: Week 26 - A to A | 6 | 6 |
| Self reported symptoms - home: Week 26 - A to missing | 1 | 0 |
| Self reported symptoms - home: Week 26 - B1 to A | 1 | — |
| Self reported symptoms - home: Week 52 - A to A | 1 | 0 |
| Self reported symptoms - home: Week 52 - A to missing | 6 | 6 |
| Self reported symptoms - home: Week 52 - B1 to missing | 1 | — |
| Self reported symptoms - school/work: Week 26 - A to A | 5 | 6 |
| Self reported symptoms - school/work: Week 26 - A to B1 | 1 | 0 |
| Self reported symptoms - school/work: Week 26 - A to missing | 1 | 0 |
| Self reported symptoms - school/work: Week 26 - B1 to A | 1 | — |
| Self reported symptoms - school/work: Week 52 - A to B1 | 1 | 0 |
| Self reported symptoms - school/work: Week 52 - A to missing | 6 | 6 |
| Self reported symptoms - school/work: Week 52 - B1 to missing | 1 | — |
The PedsQL Multidimensional Fatigue Scale measures fatigue across 3 subscales:General Fatigue, Sleep/Rest Fatigue and Cognitive Fatigue. Items are rated on a 5 point scale (0=Never to 4=Almost Always). Responses are reverse scored and linearly transformed to a 0-100 scale (0→100, 1→75, 2→50, 3→25, 4→0), with higher scores indicate less fatigue and better functioning. Subscale scores are calculated as mean of transformed item scores within each subscale. A Total Score was calculated as mean of all transformed items across subscales. If more than 50% of items are missing within a subscale or across total scale, corresponding score is not computed. If at least 50% are completed, scores are calculated as mean of non missing transformed items. All scores range from 0 (no pain) to 100 (severe pain), with higher scores indicate less fatigue. Baseline was defined as last available value prior to first dose of study drug. For participants aged 5-7 years, only parent proxy report was completed.
| score on a scale | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| General fatigue score: Week 26: 8 to 12 years of age (child report) | 0.00 ± NA | 2.08 ± 11.02 |
| General fatigue score: Week 26: 8 to 12 years of age (parent report) | -6.25 ± 2.94 | 1.04 ± 2.08 |
| General fatigue score: Week 26: 5 to 7 years of age (parent report) | 4.17 ± 7.79 | 22.92 ± 14.73 |
| General fatigue score: Week 52: 5 to 7 years of age (parent report) | 8.33 ± NA | — |
| Sleep/Rest fatigue score: Week 26: 8 to 12 years of age (child report) | -20.84 ± NA | -6.25 ± 4.17 |
| Sleep/Rest fatigue score: Week 26: 8 to 12 years of age (parent report) | 6.25 ± 8.84 | -2.09 ± 2.41 |
| Sleep/Rest fatigue score: Week 26: 5 to 7 years of age (parent report) | 5.83 ± 3.73 | -8.34 ± 11.79 |
| Sleep/Rest fatigue score: Week 52: 5 to 7 years of age (parent report) | 4.17 ± NA | — |
| Cognitive fatigue score: Week 26: 8 to 12 years of age (child report) | -8.33 ± NA | -3.12 ± 9.24 |
| Cognitive fatigue score: Week 26: 8 to 12 years of age (parent report) | 14.58 ± 2.94 | -10.42 ± 12.50 |
| Cognitive fatigue score: Week 26: 5 to 7 years of age (parent report) | -8.33 ± 17.92 | 2.09 ± 2.95 |
| Cognitive fatigue score: Week 52: 5 to 7 years of age (parent report) | -12.50 ± NA | — |
| Total score: Week 26: 8 to 12 years of age (child report) | -9.72 ± NA | -2.43 ± 7.56 |
| Total score: Week 26: 8 to 12 years of age (parent report) | 4.86 ± 4.91 | -3.82 ± 4.87 |
| Total score: Week 26: 5 to 7 years of age (parent report) | 0.55 ± 6.49 | 5.56 ± 1.96 |
| Total score: Week 52: 5 to 7 years of age (parent report) | 0.00 ± NA | — |
The PedsQL PPQ assesses current pain and worst pain intensity in the last week using a visual analog scale as well as pain location using a body map. Current and worst pain were scored separately, and scoring was based on the line length to the nearest 0.5 centimeter (5 millimeter). The score ranged from 0 (no pain) to 100 (severe pain), where higher scores indicated greater levels of pain intensity. The PedsQL PPQ was only administered in participants ages 5 years of age and older using both self-report (ages 8 and older) and parent proxy report (ages 5 and older) forms in all countries. For participants aged 5 to 7, only parents completed the questionnaire. The baseline value was defined as the last available value before the first dose of study drug.
| score on a scale | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Current pain intensity score: Week 26: 8 to 12 years of age (child report) | 1.00 ± 1.41 | 0.00 ± 0.00 |
| Current pain intensity score: Week 26: 8 to 12 years of age (parent report) | -0.50 ± 0.71 | 0.00 ± 0.00 |
| Current pain intensity score: Week 26: 5 to 7 years of age (parent report) | -10.00 ± 22.36 | 0.00 ± 0.00 |
| Current pain intensity score: Week 52: 5 to 7 years of age (parent report) | -50.00 ± NA | — |
| Worst pain intensity score: Week 26: 8 to 12 years of age (child report) | 10.00 ± 14.14 | 0.00 ± 0.00 |
| Worst pain intensity score: Week 26: 8 to 12 years of age (parent report) | -0.50 ± 0.71 | 0.00 ± 0.00 |
| Worst pain intensity score: Week 26: 5 to 7 years of age (parent report) | -15.60 ± 34.88 | 0.00 ± 0.00 |
| Worst pain intensity score: Week 52: 5 to 7 years of age (parent report) | -80.00 ± NA | — |
For Stage 2 participants, achievement of developmental milestones was planned to be assessed using the ACH developmental recording form. This form allows developmental milestones to be recorded and was not a formalized screening tool or assessment. The form measures the domains of gross motor function, fine motor function, communication and feeding via participant reports to the Investigator. The form depicts the cumulative percentage distributions for children with ACH for each item as well as norms for reference based on the Denver II test, where available. Data collected via this form was planned to be evaluated descriptively to explore the age at which participants in this study achieve developmental milestones. The baseline value was defined as the last available value before the first dose of study drug.
No measurements were reported for this outcome.
Blood samples are collected to determine plasma concentration of SAR442501.
| nanogram per milliliter (ng/mL) | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Pre-dose on Day 1 | NA ± NA | NA ± NA |
| 6 hours post dose on Day 1 | 6190 ± 3220 | 8660 ± 1350 |
| 24 hours post dose on Day 1 | 3280 ± 757 | 6260 ± 1680 |
| 72 hours post dose on Day 1 | 220 ± 188 | 728 ± 367 |
| Pre-dose on Day 57 | 215 ± 235 | 495 ± 410 |
| 3 hours post dose on Day 57 | 5000 ± 3350 | 8460 ± 3520 |
| 6 hours post dose on Day 57 | 5840 ± 2910 | 8240 ± 1770 |
| 12 hours post dose on Day 57 | 4840 ± 2360 | 8770 ± 3100 |
| 24 hours post dose on Day 57 | 2930 ± 1160 | 7050 ± 2890 |
| 72 hours post dose on Day 57 | 994 ± 689 | 2280 ± 2440 |
Blood samples are collected to determine Cmax of SAR442501. The Cmax of SAR442501 was calculated using non-compartmental method.
| ng/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Stage 1: Maximum Observed Plasma Concentration (Cmax) of SAR442501 | 6440 ± 3090 | 10000 ± 3590 |
Blood samples are collected to determine tmax of SAR442501. The tmax of SAR442501 was calculated using non-compartmental method.
| hour | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Stage 1: Time to Reach the Maximum Concentration (Tmax) of SAR442501 | 11.00 (2.72 to 24.08) | 5.75 (2.67 to 11.03) |
Blood samples are collected to determine AUC0-tau of SAR442501. The AUC0-tau of SAR442501 was calculated using non-compartmental method.
| ng*hour/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Stage 1: Area Under the Concentration Versus Time Curve From Time 0 to 72 Hours After Study Drug Administration (AUC0-tau) of SAR442501 | 226000 ± 95700 | 390000 ± 209000 |
Blood samples are collected to determine Ctrough of SAR442501. The Ctrough of SAR442501 was calculated using non-compartmental method.
| ng/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Pre-dose on Day 8 | NA ± 66.8 | 193 ± NA |
| Pre-dose on Day 29 | NA ± 112 | 961 ± 1350 |
| Pre-dose on Day 57 | 215 ± 235 | 495 ± 410 |
| Pre-dose on Day 92 | 349 ± 340 | 886 ± 649 |
| Pre-dose on Day 183 | 565 ± 516 | 2470 ± 3800 |
| Pre-dose on Day 274 | 282 ± 329 | 888 ± 201 |
| Pre-dose on Day 365 | 1230 ± NA | — |
Serum samples were collected to assess the change in CXM level with study drug. The CXM was also named PRO-C10 because the biomarker assay used was aimed to target the recognition of the C terminus of the NC1 domain of type X collagen. The baseline value was defined as the last available value before the first dose of study drug. Change from baseline in CXM level has been reported.
| picogram per mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Stage 1: Change From Baseline to Week 26 in Collagen X Biomarker (CXM) Level | 0 ± 0 | — |
Serum samples were collected to assess the change in osteocalcin level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
| microgram (mcg) per mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 7.32 ± 15.06 | 21.27 ± 14.15 |
| Week 52 | -1.99 ± NA | — |
Serum samples were collected to assess the change in bone-specific alkaline phosphatase level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
| mcg/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -3.64 ± 19.49 | -1.94 ± 15.64 |
| Week 52 | -7.28 ± NA | — |
Serum samples were collected to assess the change in P1NP level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
| mcg/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | -21.80 ± 144.40 | 83.00 ± 122.67 |
| Week 52 | -69.90 ± NA | — |
Serum samples were collected to assess the change in CTX level with study drug. The baseline value was defined as the last available value before the first dose of study drug.
| mcg/mL | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Week 26 | 0.06 ± 0.25 | 0.35 ± 0.28 |
| Week 52 | -0.01 ± NA | — |
Serum samples were collected to assess the antibodies to SAR442501. Samples were screened and then confirmed for antibodies binding to SAR442501 and the titer of confirmed positive samples were reported. Positive ADA refers to pre-existing ADA at the pre-dose assessment on Day 1.
| participants | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Stage 1: Number of Participants With Anti-drug Antibodies (ADA) to SAR442501 | 1 | 0 |
A complete neurological examination included assessment of mental status, motor function and balance, sensory exam, newborn and infant reflexes, muscle stretch reflexes in the older children and evaluation of the cranial nerves. The baseline value was defined as the last available value before the first dose of study drug.
No measurements were reported for this outcome.
Collected over SAEs, other AEs and all-cause mortality (deaths) were collected from the first dose of study drug administration (Day 1) up to early termination of the study, approximately 58 weeks (Stage 1: SAR442501 Dose A) and 46 weeks (Stage 1: SAR442501 Dose B).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: SAR442501 Dose A (Low Dose) | 0/10 (0%) | 1/10 (10%) | 5/10 (50%) |
| Stage 1: SAR442501 Dose B (High Dose) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| PneumoniaInfections and infestations | 1/10 | 0/6 |
| Event | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) |
|---|---|---|
| Blood 25-Hydroxycholecalciferol DecreasedInvestigations | 2/10 | 2/6 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 0/10 | 1/6 |
| StomatitisGastrointestinal disorders | 0/10 | 1/6 |
| RashSkin and subcutaneous tissue disorders | 0/10 | 1/6 |
| Injection Site IndurationGeneral disorders | 0/10 | 1/6 |
| LabyrinthitisInfections and infestations | 1/10 | 0/6 |
| NasopharyngitisInfections and infestations | 1/10 | 0/6 |
| PneumoniaInfections and infestations | 1/10 | 0/6 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 1/10 | 0/6 |
| ThrombocytosisBlood and lymphatic system disorders | 1/10 | 0/6 |
Enrolled population included all participants from screened population who were allocated to study drug regardless of whether the study drug was received or not, and regardless of replacement.
| Age, Continuous(years) | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) | Total |
|---|---|---|---|
| Mean | 6.8 ± 2.3 | 8.5 ± 2.5 | 7.5 ± 2.5 |
| Sex: Female, Male(Participants) | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 5 | 5 | 10 |
| Race/Ethnicity, Customized(Participants) | Stage 1: SAR442501 Dose A (Low Dose) | Stage 1: SAR442501 Dose B (High Dose) | Total |
|---|---|---|---|
| Asian | 6 | 6 | 12 |
| Black or African American | 1 | 0 | 1 |
| White | 3 | 0 | 3 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi